ADCs New
$1
In stock
Shirley
Antibody drug conjugates (ADCs) is formed by the coupling of monoclonal antibody (mAb) and small molecule drugs through the linker. The targeting of mAb to tumor cells enables small molecule drugs to play a role in specific tumor tissues, which can effectively reduce the high toxic side effects of traditional small molecule drugs and improve the overall treatment efficiency. Currently, there are 13 ADC drugs on the market worldwide. According to Grandview data, as ADCs come on the market one after another and indications expand to more disease areas, the industry scale of ADCs will maintain rapid growth in the future, and it is estimated that the market scale will reach 21 billion US dollars in 2025, and the compound growth rate will exceed 50% in 2020-2025. https://www.creative-diagnostics.com/antibody-drug-conjugates-adcs.htm
Antibody drug conjugates (ADCs) is formed by the coupling of monoclonal antibody (mAb) and small molecule drugs through the linker. The targeting of mAb to tumor cells enables small molecule drugs to play a role in specific tumor tissues, which can effectively reduce the high toxic side effects of traditional small molecule drugs and improve the overall treatment efficiency. Currently, there are 13 ADC drugs on the market worldwide. According to Grandview data, as ADCs come on the market one after another and indications expand to more disease areas, the industry scale of ADCs will maintain rapid growth in the future, and it is estimated that the market scale will reach 21 billion US dollars in 2025, and the compound growth rate will exceed 50% in 2020-2025. https://www.creative-diagnostics.com/antibody-drug-conjugates-adcs.htm
0 Comments 0 Shares 1462 Views